News
HKMPF
23.00
+7.78%
1.66
Weekly Report: what happened at HKMPF last week (1019-1023)?
Weekly Report · 2d ago
Weekly Report: what happened at HKMPF last week (1012-1016)?
Weekly Report · 10/19 09:11
Hikma Pharmaceuticals price target lowered to 1,810 GBp from 1,870 GBp at Citi
TipRanks · 10/13 19:45
Hikma Pharmaceuticals (HIK) Gets a Buy from Citi
TipRanks · 10/13 10:37
Weekly Report: what happened at HKMPF last week (1005-1009)?
Weekly Report · 10/12 09:12
Weekly Report: what happened at HKMPF last week (0928-1002)?
Weekly Report · 10/05 09:12
Weekly Report: what happened at HKMPF last week (0921-0925)?
Weekly Report · 09/28 09:11
Jefferies Reaffirms Their Buy Rating on Hikma Pharmaceuticals (HIK)
TipRanks · 09/25 14:35
Hikma names ViiV finance chief Rebecca Hall as new CFO
TipRanks · 09/24 06:08
Hikma launches investor spotlight series on R&D strategy
TipRanks · 09/22 11:02
Hikma Executives Reinvest Dividends in Company Shares via DRIP
TipRanks · 09/22 08:37
Weekly Report: what happened at HKMPF last week (0914-0918)?
Weekly Report · 09/21 09:11
Weekly Report: what happened at HKMPF last week (0907-0911)?
Weekly Report · 09/14 09:12
Berenberg Bank Sticks to Its Buy Rating for Hikma Pharmaceuticals (HIK)
TipRanks · 09/11 09:35
Hikma Pharmaceuticals upgraded to Equal Weight from Underweight at Barclays
TipRanks · 09/08 08:40
Barclays upgrades Hikma Pharmaceuticals (HIK) to a Hold
TipRanks · 09/08 06:36
Weekly Report: what happened at HKMPF last week (0831-0904)?
Weekly Report · 09/07 09:11
Weekly Report: what happened at HKMPF last week (0824-0828)?
Weekly Report · 08/31 09:12
Hikma completes $250m share buyback, reshaping capital structure
TipRanks · 08/28 06:13
Hikma Executives Restructure Pledges Over 2 Million Shares via Darhold
TipRanks · 08/24 14:07
More
Webull provides a variety of real-time HKMPF stock news. You can receive the latest news about Hikma Pharma through multiple platforms. This information may help you make smarter investment decisions.
About HKMPF
Hikma Pharmaceuticals PLC is a multinational pharmaceutical company engaged in the development, manufacturing and marketing of a broad range of generic, branded and specialty pharmaceutical products. Its pharmaceutical operations are conducted through three business segments: Injectables, Branded and Hikma Rx. It supplies hospitals across North America, Europe and the Middle East and North Africa (MENA) region with generic injectable and specialty medicines, supported by its growing global manufacturing network. It supplies branded generic and in-licensed products from its local manufacturing facilities to retail and hospital customers across the MENA region. Through Hikma Rx, it supplies oral, respiratory and other generic and specialty products to the North American market. Its manufacturing facilities in the United States (US) supply products across a broad range of therapeutic areas, including respiratory, oncology and pain management, serving customers in both the US and Canada.